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Cytokine Regulation in Human CD4
T Cells by the Aryl Hydrocarbon
Receptor and Gq-Coupled
Receptors
Jeremy P. McAleer1, Jun Fan2, Bryanna Roar1, Donald A. Primerano2 & James Denvir2
Th17 cells contribute to host defense on mucosal surfaces but also provoke autoimmune diseases when
directed against self-antigens. Identifying therapeutic targets that regulate Th17 cell differentiation
and/or cytokine production has considerable value. Here, we study the aryl hydrocarbon receptor (AhR)dependent transcriptome in human CD4 T cells treated with Th17-inducing cytokines. We show that
the AhR reciprocally regulates IL-17 and IL-22 production in human CD4 T cells. Global gene expression
analysis revealed that AhR ligation decreased IL21 expression, correlating with delayed upregulation
of RORC during culture with Th17-inducing cytokines. Several of the AhR-dependent genes have known
roles in cellular assembly, organization, development, growth and proliferation. We further show that
expression of GPR15, GPR55 and GPR68 positively correlates with IL-22 production in the presence of
the AhR agonist FICZ. Activation of GPR68 with the lorazepam derivative ogerin resulted in suppression
of IL-22 and IL-10 secretion by T cells, with no effect on IL-17. Under neutral Th0 conditions, ogerin and
the Gq/11 receptor inhibitor YM254890 blunted IL-22 induction by FICZ. These data reveal the AhRdependent transcriptome in human CD4 T cells and suggest the mechanism through which the AhR
regulates T cell function may be partially dependent on Gq-coupled receptors including GPR68.
CD4 T helper cells direct immune responses by differentiating into specialized subsets named Th1, Th2, Th17
and regulatory T cells (Tregs)1. The balance of subsets generated in response to the cytokine milieu profoundly
influences inflammatory disease outcomes. Although CD4 T cells are classified by their effector cytokines (Th1/
IFN-γ, Th2/IL-4, Th17/IL-17, Treg/IL-10), it is now understood that they are plastic and retain the potential to
differentiate into other subsets2. The multi-functional potential of CD4 T cells along with their antigen specificity
makes them attractive therapeutic targets.
Th17 cells contribute to host defense against bacteria and fungi on mucosal surfaces but may induce chronic
inflammatory diseases when directed against innocuous antigens3. The differentiation of naïve CD4 T cells into
effector Th17 cells in lymph nodes is facilitated by antigen, IL-6, TGF-β, IL-1β and IL-23, resulting in the production of IL-17. Some Th17 cells also produce IL-22, IL-10 or IFN-γ which can have pro- or anti-inflammatory
properties4,5. The receptors for IL-17 and IL-22 are primarily localized to mucosal surfaces including the gastrointestinal (GI) tract and lungs6,7. While IL-17 stimulates G-CSF secretion from epithelial cells leading to neutrophil
recruitment, IL-22 induces antimicrobial peptide secretion and epithelial repair following injury8. Several models
have demonstrated a role for IL-17 in chronic inflammation3. On the other hand, IL-22 and IL-10 protect against
colitis9,10. Thus, there is considerable interest in understanding how pro- and anti-inflammatory cytokines are
regulated in human Th17 cells.
The aryl hydrocarbon receptor (AhR) is activated by many endogenous ligands and natural products that have
disparate effects on inflammation and T cells11. During Th17 cell differentiation, the AhR is upregulated and can
increase production of the effector cytokines IL-17 and IL-2212. Notably, the AhR ligands FICZ or 2,3,7,8-tetra
chlorodibenzo-p-dioxin (TCDD) can induce Th17 or Treg differentiation, respectively, resulting in increased or
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Figure 1. Effect of AhR modulators on human CD4 T cell differentiation. Naïve human CD4 T cells were
cultured with Th17-inducing cytokines (IL-1β, IL-6, IL-23, TGF-β) in the presence or absence of FICZ or
CH223191 for 1–8 days. (A) Gene expression in cultures at daily intervals, normalized to the housekeeping
gene HPRT. Data are combined from 3 experiments (n = 3) and shown as mean+/− SEM. (B) Cytokine levels
in culture supernatants on days 6–8 measured by ELISA. Data are combined from 8 experiments (n = 7–8).
LOD = limit of detection.

decreased susceptibility to experimental autoimmune encephalomyelitis13. The mechanism underlying pro- versus anti-inflammatory effects of AhR activation in T cells remains unclear.
Proton-sensing G-protein-coupled receptors (GPR4, 65, 68, 132) are heterotrimeric complexes that sense
extracellular changes in pH14. Ischemia and chronic inflammation promote extracellular acidification through
the stimulation of anaerobic glycolysis. The activation of proton-sensing GPRs can lead to the expression of
inflammatory mediators including COX-2, prostaglandins and cytokines14. GPR68 is expressed in several cell
types including the immune system and transmits signals through Gq/11 proteins under acidic conditions, leading
to the activation of phospholipase C (PLC), inositol triphosphate and intracellular Ca2+ mobilization. GPR68 is
fully active at pH 6.815. Notably, Gq/11 signaling regulates murine Th17 responses in vivo16, suggesting a potential
role for the GPR68/Gq/11 pathway in T cell differentiation.
We examined the AhR on human CD4 T cells cultured with or without Th17-inducing cytokines. In contrast
to mouse studies12,13, FICZ suppressed IL-17 production from human CD4 T cells. To study the mechanism of
AhR regulation of cytokine production, we performed RNA-seq on T cells derived from peripheral blood of six
healthy human volunteers treated with an agonist or antagonist. The AhR regulated several genes involved in
cellular assembly, organization, development, growth and proliferation. The expression of G-protein-coupled
receptor 68 (GPR68) positively correlated with IL-22 and was studied further. Activation of GPR68 with a
positive allosteric modulator suppressed IL-22 and IL-10 production from human CD4 T cells cultured with
Th17-inducing cytokines. Under neutral Th0 conditions, ogerin and the Gq/11 inhibitor YM254890 partially suppressed IL-22 induction by FICZ. These data suggest that pro- versus anti-inflammatory effects of AhR may be
partially regulated by Gq/11 receptors including GPR68. We speculate this pathway may regulate inflammation in
peripheral tissues with extracellular acidification.

Results and Discussion

Time course of human Th17 cell gene expression. To determine the kinetics of gene expression associ-

ated with human Th17 cell differentiation in the presence of AhR modulators, naïve CD4 T cells from peripheral
blood of healthy volunteers were cultured with Th17-inducing cytokines (IL-6, TGF-β, IL-1β, IL-23) for 1–6
days. Serum-free RPMI was used as the cell culture medium in order to minimize AhR activation in control
groups4. Although optimal Th17-differentiation conditions include neutralizing antibodies against IFN-γ, IL-2
and IL-44,17, we chose not to use neutralizing antibodies in order to test if AhR activation of human CD4 T cells
promotes differentiation into non-Th17 subsets. These conditions resulted in heterogeneous T helper cell populations in our cultures. Experimental cultures were treated with the AhR agonist FICZ (200 nM) or antagonist
CH223191 (4uM). Th17-inducing cytokines resulted in a sustained increase in expression of the AhR target gene
CYP1A1 compared to freshly isolated naïve CD4 T cells (Fig. 1A). The addition of FICZ to Th17 cultures further
increased CYP1A1 by an order of magnitude, while CH223191 potently suppressed CYP1A1. Thus, treating CD4
T cells with FICZ or CH223191 resulted in AhR activation or inhibition, respectively. Expression of the master
Th17 cell transcription factor RORC decreased by 50 percent between days 1 and 2 of culture, followed by a 2-fold
increase between days 2 and 3 (Fig. 1A). RORC expression peaked on day 5 at levels 4.5-fold higher than observed
Scientific REPOrTs | (2018) 8:10954 | DOI:10.1038/s41598-018-29262-4
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Figure 2. CD4 T cell phenotype in serum-free RPMI. Human peripheral blood naïve CD4 T cells were purified
by negative selection and cultured for five days with plate-bound anti-CD3 and soluble anti-CD28. Additional
treatment groups included Th17-inducing cytokines (IL-1β, IL-6, IL-23, TGF-β), AhR agonist (FICZ, 200 nM)
or AhR antagonist (CH223191, 4 uM), as indicated. On day 5, T cells were restimulated with PMA and
ionomycin in the presence of brefeldin A for 4 hours, stained with fluorescent-labelled antibodies and analyzed
by flow cytometry. Shown are representative dot plots of CD4 versus FoxP3 on live cells (top) or IL-22 versus
IL-17 on CD4+ FoxP3− cells (bottom).

on day 2. FICZ delayed the upregulation of RORC on days 3 and 4, consistent with a suppressive effect on Th17
cell differentiation. In the presence of Th17-inducing cytokines, treatment with CH223191 prevented the downregulation of RORC, resulting in a 40 percent increase between days 1 and 2 (Fig. 1A). This effect was dependent on Th17-inducing cytokines, as RORC was downregulated from days 1–4 in Th0 cultures with CH223191
(Supplementary Fig. S1). These data suggest that the activated AhR can delay RORC upregulation during human
Th17 cell differentiation. This effect was not associated with conversion to a regulatory T cell (Treg) or Th1 cell
phenotype, as FOXP3 and TBX21 expression were not significantly affected by the AhR modulators in the presence of Th17-inducing cytokines (Fig. 1A).

Reciprocal regulation of IL-17 and IL-22 secretion by human CD4 T cells through the aryl hydrocarbon receptor. Next, cytokines were measured in culture supernatants on days 6–8. Control cultures

incubated without additional differentiation cytokines produced very little IL-17 (Fig. 1B, Media). Treatment
with Th17-inducing cytokines significantly increased IL-17 secretion (1881pg/mL +/− 1020). Addition of FICZ
to Th17 cultures reduced IL-17 by 71 percent on average (539 pg/mL +/− 229), demonstrating that the AhR
inhibits Th17 differentiation. This inhibitory effect of FICZ was also observed for IL-10 production (Fig. 1B). In
contrast, the inhibitor CH223191 resulted in a trend towards increased IL-17 secretion. Although FICZ has been
shown to increase IL-22 production from human CD4 T cells18, the addition of FICZ to cultures containing Th17
inducing cytokines did not significantly increase IL-22 (Fig. 1B). Pairwise analysis revealed that FICZ increased
IL-22 in six out of eight donors. Further, FICZ significantly increased IL-22 in the absence of exogenous cytokines
(Supplementary Fig. S2). It has been reported that TGF-β suppresses IL-22 and AhR function19–23. To determine
if TGF-β suppresses IL-22 induction by FICZ, T cells were cultured with IL-6, IL-1β, IL-23 and the TGF-β receptor I inhibitor Galunisertib. These “Th22” conditions significantly increased IL-22 production compared to culture with Th17-inducing cytokines (Supplementary Fig. S2). Notably, FICZ had no effect on IL-22 when T cells
were cultured with exogenous cytokines, suggesting that AhR stimulation did not synergize with inflammatory
cytokines.
Nevertheless, the AhR was required for IL-22 production, as CH223191 potently decreased IL-22 levels by
88 percent. Flow cytometric analysis revealed that IL-17 and IL-22 were produced by distinct cell populations,
as there were very few IL-17+ IL-22+ double-producing cells (Fig. 2). The frequency of cells producing either
IL-17 or IL-22 was less than one percent due to culturing under suboptimal Th17 differentiation conditions in
Scientific REPOrTs | (2018) 8:10954 | DOI:10.1038/s41598-018-29262-4
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Figure 3. Differentially expressed genes in Th17 cell cultures on day 3. Naïve human CD4 T cells were cultured
under four conditions for three days (media, Th17-inducing cytokines (Th17 conditions), Th17 + FICZ,
Th17 + CH223191), followed by RNA-seq. Left: Venn diagram showing the number of differentially expressed
genes for each condition compared to the Th17 group. Overlapping areas of circles represent genes regulated by
multiple treatments. Right: Heat map showing relative expression of the genes regulated by all three treatments
compared to the media control.

serum-free RPMI; thus, it is likely that the majority of IL-17 and IL-22 detected by ELISA (Fig. 1B) was derived
from ~103 cells. Overall, early changes in gene expression caused by AhR modulators (Fig. 1A, days 1–3) correlated with later effects on cytokine production (Fig. 1B, days 6–8), suggesting the AhR regulates early stages of
Th17 differentiation.

CD4 T cell transcriptome during culture with Th17-inducing cytokines and AhR modulators. To gain insight into the mechanism of how AhR regulates human Th17 cell differentiation, we performed

RNA-seq on day 3 cultures in the presence or absence of AhR modulators. This time point was chosen because
induction of the Th17 cell marker RORC was first observed on day 3 and delayed by FICZ treatment (Fig. 1A),
suggesting the AhR regulates early Th17 cell gene expression. Supernatant cytokines were approximately 10-fold
lower on day 3 (Supplementary Fig. S3) compared to days 6–8. At this time point, Th17-inducing cytokines
significantly increased IL-17 and IFN-γ production; however, the addition of FICZ or CH223191 had no effect
on cytokines measured in day 3 culture supernatants (Supplementary Fig. S3). Illumina TruSeq mRNA libraries
were prepared from total RNA and sequenced using the Illumina HiSeq1500 platform. Data from six individual
donors were pooled and differentially expressed genes between each treatment and the control were identified
(Fig. 3). In total, 975 genes were significantly up- or down-regulated in cultures with Th17-inducing cytokines
compared to media controls cultured with anti-CD3 and anti-CD28 only. Ingenuity pathway analysis revealed
that most of these genes were involved in cell death or survival, gene expression, cell cycle or protein synthesis
(Table 1). The addition of FICZ to cultures with Th17-inducing cytokines altered the expression of 88 genes, while
Th17 + CH223191 treatment significantly affected 142 genes compared to the Th17 group. Notably, the AhR agonist FICZ regulated genes involved in small molecule biochemistry and lipid metabolism, while the AhR inhibitor
CH223191 primarily affected the expression of genes involved in cellular assembly, organization, development,
growth, proliferation and cell cycle. Several genes were co-regulated by 2 or more treatments (Fig. 3, Venn diagram overlapping regions of circles).
Many genes with known roles in CD4 T cell differentiation were not significantly affected by treatments on day
3 (Fig. 4A); however, Th17-inducing cytokines resulted in a significant increase in IL21, encoding for an autocrine
cytokine required for Th17 differentiation24,25. FICZ treatment prevented the upregulation of IL21 expression
(Fig. 4A). This was associated with a modest decrease in RORC and increase in GATA3 expression compared
to cultures treated with Th17-inducing cytokines, consistent with previous studies demonstrating an inhibitory
effect of the AhR on Th17 differentiation26,27 and suppression of Th2 differentiation by IL-2128. Conversely, the
AhR inhibitor increased IL21 expression compared to Th17 cultures. Although IL-21 can enhance the binding
of AhR to the IL22 promoter29, we observed an inverse correlation between IL21 expression (Fig. 4A) and IL-22
production (Fig. 1B).

Genes suppressed by the AhR. In addition to IL21, several other genes were identified that have not
previously been reported to be AhR-regulated. In comparison to Th17-treated cultures, treatment with the AhR
inhibitor CH223191 increased the expression of ABI2 (1.6-fold), CARD14 (1.5-fold), CD160 (1.7-fold), FOXH1
(1.5-fold), LIG3 (1.5-fold), MPHOSPH8 (1.4-fold), PPP1R18 (1.6-fold) and TMEM50B (1.5-fold) (Supplementary
Fig. S4). ABI2 contributes to T cell receptor induced proliferation by enhancing signaling through the T cell
receptor and providing costimulation30. On the other hand, CD160 inhibits human CD4 T cell proliferation and
IFN-γ production by interacting with herpesvirus entry mediator31. FOXH1 is involved in TGF-β-dependent
transcription by interacting with SMAD2 and SMAD432. Thus, the AhR may suppress TGF-β function through
Scientific REPOrTs | (2018) 8:10954 | DOI:10.1038/s41598-018-29262-4
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Media

Th17 + FICZ

Cell function

Genes

p-values

Cell death and
survival

319

4.6 × 10

Gene expression

223

Cell cycle

Th17 + CH223191

Cell function

Genes

p-values

Cell function

Small molecule
biochemistry

Genes

p-values

10

−2

7.8 × 10 – 5.0 × 10

Cellular assembly and
organization

18

5.9 × 10−5 – 9.0 × 10−3

1.3 × 10−16 – 9.6 × 10−6

Lipid metabolism

5

7.8 × 10−6 – 3.3 × 10−2

Cellular development

15

2.0 × 10−5 – 8.9 × 10−3

168

9.7 × 10−14 – 2.0 × 10−5

Nucleic acid
metabolism

3

2.2 × 10−4 – 2.8 × 10−2

Cell cycle

14

5.9 × 10−5 – 9.2 × 10−3

Protein synthesis

108

3.0 × 10−22 – 9.6 × 10−6

Vitamin
and Mineral
Metabolism

3

1.6 × 10−4 – 3.6 × 10−2

Cellular growth and
proliferation

14

3.0 × 10−5 – 9.2 × 10−3

RNA posttranscriptional
modification

60

1.2 × 10−22 – 2.2 × 10−6

Drug metabolism

2

2.4 × 10−5 – 2.8 × 10−2

Cell morphology

10

2.0 × 10−5 – 8.9 × 10−3

−42

– 1.9 × 10

−5

−6

Table 1. Most common cellular functions for genes differentially expressed by each condition relative to Th17
treatment. Numbers of differentially expressed genes in functional categories, identified by Ingenuity Pathway
Analysis. This platform reports p-values for the overlap of specific subcategories of each functional category
under the null hypothesis that the set of differentially expressed genes is independent of the subcategory. The
range of p-values over these subcategories is indicated.

inhibition of FOXH1 expression. This may contribute to reduced levels of RORC observed in cultures treated
with FICZ (Fig. 1). CARD14 can activate NF-κB to induce pro-inflammatory cytokines, and gain of function
mutations in CARD14 are associated with psoriasis33. Circulating Th17 cells are increased in patients with psoriasis, and NF-κB blockade inhibits cytokine production from these Th17 cells34. It is intriguing to hypothesize
that CARD14 suppression by AhR agonists can inhibit Th17 cell cytokine production in patients with psoriasis.
Di Meglio, et al. has reported anti-inflammatory effects of AhR agonists in lesional skin of psoriasis patients35.
The same study found that AhR-deficient mice have exacerbated skin inflammation in response to imiquimod,
demonstrating that the AhR protects against experimental psoriasis.
Genes that were suppressed by FICZ treatment included AIM1 (1.8-fold), ANAPC1P1 (2.1-fold), BASP1
(1.2-fold), CCR3 (3.6-fold), CD48 (2.0-fold), PRR34 (1.6-fold), PTMS (1.8-fold), SBF2 (1.6-fold) and VTI1B
(1.6-fold) (Fig. 4). BASP1 was previously shown to be expressed in human Th17 cells36, although its function in T
cells is not known. CD48 is a costimulatory molecule that was found to be expressed in encephalogenitic T cells
producing IL-17, IFN-γ and GM-CSF37. These data provide further support that AhR activation inhibits phenotypic changes in human CD4 T cells associated with Th17 cell differentiation. Overall, it remains to be determined
if AhR-dependent genes are directly or indirectly regulated through AhR-mediated suppression of RORC.

Genes upregulated by the AhR.

Among the genes suppressed by CH223191 treatment were BCL9L
(1.5-fold), CD96 (2.1-fold), GPR15 (3.9-fold), GPR68 (2.2-fold), GSG2 (1.9-fold) and ITGAE (1.3-fold)
(Supplementary Fig. S4). CD96 is a member of the immunoglobulin superfamily with an ITIM-like domain,
suggesting it may have an inhibitory effect on T cell costimulation38. ITGAE encodes for CD103, an E-cadherin
receptor expressed on tissue-resident memory T cells39. ITGAE was found to be expressed by IL-17+ Foxp3+ T
cells, indicating it can be used as a marker to identify Th17 cells that are transdifferentiating into Tregs40. On
the other hand, CD103+ CD4 T cells express higher levels of IL-17, IFN-γ and TNF than CD103- CD4 T cells in
patients with ulcerative colitis41, suggesting this subset can drive intestinal inflammation. The upregulation of
CD103 in response to TGF-β appears to play a role in the retention of memory T cells in mucosal tissues through
its interactions with epithelial E-cadherin39. In vivo, AhR activation with TCDD was found to increase the number of splenic CD103+ CD11c+ dendritic cells42, suggesting the AhR can promote Treg differentiation through its
effects on dendritic cells.
Genes that were upregulated by FICZ treatment included ANKRD13C (4.4-fold), CYP1B1 (3.3-fold), PRCD
(4.6-fold), S1PR4 (2.1-fold), TREH (3.7-fold) and ZBTB21 (4.3-fold) (Fig. 4B). Of note, ANKRD13C is a molecular chaperone for G protein-coupled receptors (GPRs)43, several of which have been shown to regulate T cell
function. Therefore, we hypothesized that the AhR regulates T cell cytokine production through GPR upregulation. In support, GPR15 was increased by FICZ and decreased by CH223191 in Th17 cultures (Supplementary
Fig. S4). GPR15 is a colon-specific trafficking molecule enriched on peripheral Tregs44. Murine models have
demonstrated a role for GPR15 in T cell-dependent colitis45, although most data suggests that GPR15 regulates
gut homing rather than cytokine production from T cells. FICZ prevented the downregulation of GPR55 and
GPR68 observed during Th17 differentiation (Figs 3, 5). GPR55 is a cannabinoid receptor expressed in immune
cells, the GI tract and brain46. Activation of GPR55 increases intracellular calcium through Gq/11 and phospholipase C47. Experimental colitis models have demonstrated that GPR55 agonists and antagonists are capable of
protecting against intestinal inflammation48,49, demonstrating complex roles for GPR55 and cannabinoids in the
gut. Currently, the impact of endogenous GPR55 signaling on T cell differentiation is not known, although it was
shown to activate the NFAT transcription factor in transfected cells50, suggesting that GPR55 may influence T cell
receptor signaling. GPR68, or ovarian cancer G-protein-coupled receptor 1 (OGR1), is a proton-sensing receptor
activated by extracellular acidification15. This receptor is widely expressed in the immune system, small intestine,
lungs and brain, among other tissues51. GPR68 activation increases intracellular Ca2+ concentrations through
Gq/1152. Since several chronic inflammatory diseases are associated with extracellular acidification14, the impact of
GPR68 activation on Th17 cell cytokine production was further examined.
Scientific REPOrTs | (2018) 8:10954 | DOI:10.1038/s41598-018-29262-4
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Figure 4. Early Th17 cell gene expression in the presence of AhR modulators. (A) Heat map of selected genes
associated with CD4 T cell differentiation for each treatment relative to the media control. (B) Heat map of
genes significantly regulated by FICZ compared to cultures containing Th17-inducing cytokines (Th17) without
FICZ.

GPR68 negatively regulates IL-22 and IL-10 production from differentiating CD4 cells. Among
the four proton-sensing GPRs, only GPR68 was significantly increased by FICZ treatment (Fig. 5). Gaublomme
et al. found that GPR65 is upregulated on pathogenic Th17 cells53; however, AhR modulators did not influence
GPR65 expression during the six day culture (Fig. 5). To determine the role of GPR68 activation in human Th17
cell differentiation, a lorazepam-derived positive allosteric modulator named ogerin was used54. Naïve CD4 T
cells were cultured under Th17 conditions with or without AhR modulators, as described above. Treatment with
ogerin suppressed IL-22 and IL-10 production in cultures treated with Th17-inducing cytokines, but had no effect
on IL-17 (Fig. 6). To our knowledge this is the first demonstration of feedback inhibition on IL-22 production
following AhR activation. This finding may have implications for inflammatory bowel diseases (IBDs), as IL-22
protects against chemical-induced colitis10. In addition, patients with IBD have increased GPR68 expression in
intestinal mucosa55. This study also found that endogenous Gpr68 expression contributes to spontaneous intestinal inflammation in the Il10−/− mouse model. Mice deficient in Gpr68 are resistant to experimental autoimmune
Scientific REPOrTs | (2018) 8:10954 | DOI:10.1038/s41598-018-29262-4
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Figure 5. Expression of proton-sensing GPRs in Th17 cell cultures. (A) Heat map of proton-sensing GPRs
from day 3 cultures. Data are from the same experiments described in Figs 3 and 4. Empty sections indicate that
GPR4 was not expressed. (B) and (C) Expression of GPR65 and GPR68 in cultures containing Th17-inducing
cytokines (Th17), measured by real-time PCR each day for 6 days, as indicated. Data are from the same
experiments described in Fig. 1A.

encephalomyelitis, correlating with fewer Th1 and Th17 cells56. These data demonstrate that a positive allosteric
modulator of GPR68 suppresses IL-22 and IL-10 secretion from CD4 T cells in the presence of Th17-inducing
cytokines.

Gq-coupled receptors suppress spontaneous IL-22 secretion from human CD4 T cells. To deter-

mine if GPR68 regulates T cell function under non-differentiating (Th0) conditions, naïve CD4 T cells were cultured without exogenous cytokines in the presence of plate-bound anti-CD3 and soluble anti-CD28 antibodies
for three days. FICZ treatment significantly increased IL-22 secretion compared to control medium (IMDM
with 10% FBS; Fig. 7A). Ogerin partially suppressed the induction of IL-22 by FICZ (Fig. 7A), similar to cultures
with Th17-inducing cytokines (Fig. 6A). The Gq/11 receptor inhibitor YM254890 had a similar effect as ogerin,
partially suppressing IL-22 induction by FICZ under Th0 conditions (Fig. 7A). This supports our hypothesis that
AhR-dependent IL-22 production is regulated by Gq-coupled receptors. Inhibiting the AhR with CH223191
significantly increased IL-10 secretion compared to media alone (Fig. 7B). Although ogerin or YM254890 treatment resulted in a trend towards decreased IL-10, this effect was not statistically significant. We observed that
35 percent of CD4 T cells in the Th0 cultures expressed the regulatory T cell (Treg) transcription factor Foxp3
(Fig. 7C). Treatment with CH223191 or YM254890 significantly decreased the percent of CD4 T cells expressing
Foxp3, suggesting a potential role for the AhR and Gq-coupled receptors in Treg differentiation. Overall, our data
indicate the mechanism through which the AhR regulates human CD4 T cell function may be partially dependent
on Gq/11-coupled receptors such as GPR68 and GPR55. In future studies, it will be interesting to measure these
receptors on ex vivo-isolated Th17 and Th22 cells.

Conclusions

The regulation of cytokine production by human Th17 cells has clinical relevance for several chronic inflammatory diseases in which Th17 cells play a role. Interleukin-1β produced by innate immune cells supports
pro-inflammatory functions of Th17 cells, in part by suppressing IL-105,57. Our data demonstrate that AhR ligation with FICZ also suppresses IL-10 (Figs 1B and 6B), suggesting this may contribute to its pro-inflammatory
effects. Murine models have demonstrated that pathogenic Th17 cells produce GM-CSF58,59. In human CD4 T
cells, IL-23 suppresses GM-CSF production while IL-2 and IL-12 increase GM-CSF60. Consistent with this, we
observed that CSF2 significantly decreased when T cells were cultured with the combination of IL-1β, IL-6, IL-23
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Figure 6. Enforced GPR68 stimulation inhibits IL-22 and IL-10 production from human CD4 T cells. Naïve
CD4 T cells were cultured with Th17-inducing cytokines (Th17) for six days in the presence or absence of FICZ
or CH223191, as indicated. Experimental groups were treated with (open bars) or without (closed bars) ogerin.
On day 6, IL-22 (A), IL-10 (B), IL-17 (C) and IFN-γ (D) were measured in culture supernatants. Shown are the
Mean+/− SEM from four experiments with n = 8.

and TGF-β. In our model, AhR modulators had no effect CSF2 expression. The role of T cell-derived GM-CSF in
human disease remains to be clarified.
Cytokine production by CD4 T cells is accompanied by their upregulation of tissue homing receptors. Duhen
et al. identified a subset of skin-homing memory T cells producing IL-22 but not IL-1761. This population of Th22
cells expresses CCR4, CCR6 and CCR10 in response to IL-6 and TNF stimulation. On the other hand, IL-17 was
found to be produced by CCR4+ CCR6+ CCR10- cells, demonstrating that expression of CCR10 can distinguish
Th17 and Th22 subsets. These chemokine receptors were not regulated by FICZ or CH223191 in our study, suggesting a limited role for the AhR in tissue trafficking. Alternatively, the day 3 time point may not have been optimal to measure chemokine receptors. Our pathway analysis revealed several AhR-dependent genes to be involved
in cell growth, development and proliferation. In the future, it will be interesting to examine the role of GPR68 in
cytokine production by memory CCR4+ CCR6+ CCR10+ and CCR4+ CCR6+ CCR10- CD4 T cell subsets.
In summary, we identified several gene targets of the AhR regulating CD4 T cell proliferation, differentiation
and function. We further demonstrated that Gq-coupled receptors such as GPR55 or GPR68 may be involved in
T cell cytokine production in response to AhR ligands. Our data showing a role for the proton-sensing receptor
GPR68 in suppressing IL-22 and IL-10 production suggests that extracellular acidification may regulate T cell
function through a receptor-dependent mechanism. Several chronic inflammatory diseases are associated with
extracellular acidification including asthma, arthritis, atherosclerosis and tumors14. Gq-coupled receptors have
been implicated in lupus and rheumatoid arthritis62. Further studies are warranted to investigate cell type-specific
functions of GPR55 or GPR68 in chronic inflammatory diseases.

Methods

Th17 cell culture.

Blood samples from healthy human volunteers were obtained from Zen-Bio, Inc.,
Research Triangle Park, NC. Each volunteer signed IRB or FDA informed consent forms validated by Pearl
Pathways, LLC. Samples were processed according to Standard Operating Procedure managed Good Laboratory
Practice protocols in compliance with all legal and ethical regulations. Peripheral blood mononuclear cells
(PBMCs) were isolated from human buffy coat by density gradient centrifugation. Briefly, buffy coat was diluted
1:3 in PBS, overlayed onto Ficoll-Paque PLUS (GE Healthcare) and centrifuged at 400 × g for 20 min with the
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Figure 7. Gq-coupled receptors decrease IL-22 secretion and Foxp3 expression in human CD4 T cells.
Naïve human CD4 T cells were cultured in IMDM, 10% FBS and anti-CD3/CD28 antibodies for three days.
Experimental groups received FICZ, CH223191, ogerin or the Gα (q/11) inhibitor YM254890, as indicated.
IL-22 (A) and IL-10 (B) were measured in culture supernatants by ELISA. (C,D). Day 3 flow cytometry staining
for Foxp3, gated on CD4 T cells. Data are combined from two experiments with n = 5–6.
brake off. The cloudy interface containing PBMCs was washed with PBS, centrifuged (450 × g, 5 min) and resuspended in PBS with 2% FBS and 1 mM EDTA. Naïve CD4 T cells were purified using a commercially available
kit (StemCell Technologies, Vancouver, BC, Canada). Following purification, cells were resuspended in RPMI
with serum replacement factor 3 (Sigma-Aldrich, St. Louis, MO), anti-CD28 clone CD28.2 (2 ug/mL; Biolegend,
San Diego, CA), L-glutamine and penicillin-streptomycin. Cells were enumerated using trypan blue exclusion,
and 0.5–1.0 × 106 were seeded in 24 well plates pre-coated the day before with anti-human CD3 clone OKT3 or
UCHT-1 (10 ug/mL; Biolegend). In some experiments, 0.1 × 106 cells were seeded in 96 well plates pre-coated
with anti-CD3 clone UCHT-1 (10 ug/mL). CD4 T cell purity ranging from 90–98 percent was verified by flow
cytometry.
Recombinant human cytokines were purchased from R&D Systems. Th17 conditions included culturing
naïve CD4 T cells with IL-6 (30 ng/mL), TGF-β (2 ng/mL), IL-1β (10 ng/mL) and IL-23 (10 ng/mL). Th22 culture conditions were IL-1β, IL-6, IL-23, Galunisertib (10 uM), anti-IL-4 (0.5 ug/mL), anti-IFN-γ (0.5ug/mL) in
IMDM with 10% fetal bovine serum. Th0 culture conditions, or Media, were plated-bound anti-CD3 and soluble
anti-CD28. Additional treatments included FICZ (200 nM; Sigma-Aldrich), CH223191 (4 uM; Sigma-Aldrich),
ogerin (10 uM; Tocris Bioscience) and YM254890 (1 uM; Adipogen Life Sciences).

RNA quantitation and RT-PCR. Total RNA was purified from T cell cultures using TRIzol reagent
(Ambion) and quantitated by spectrophotometry (NanoDrop Lite, Thermo Scientific). For quantitative real-time
PCR, 1ug of RNA was used as a template for reverse transcription into cDNA (iScript, Bio-Rad). PCR reactions
were performed using TaqMan Gene Expression Master Mix and commercially available primers labeled with
FAM-MGB (Applied Biosystems). PCR reactions were run on a QuantStudio 3 (Applied Biosystems) with the
following conditions: 50 C for 2 min, 95 C for 10 min, and 40 cycles of 95 C for 15 sec and 60 C for 1 min. Target
gene expression was normalized to the housekeeping gene HPRT and analyzed using the delta-delta Ct method63.
RNA-Seq and data analysis.

Naïve CD4 T cells from peripheral blood of six healthy human volunteers
were cultured in serum-free RPMI and serum replacement factor 3 (Sigma-Aldrich) under four experimental
conditions: (1) anti-CD3 and anti-CD28 antibodies (control medium), (2) Th17 differentiation conditions (IL-6,
TGF-β, IL-1β, IL-23), (3) Th17 + FICZ (AhR agonist) and (4) Th17 + CH223191 (AhR antagonist). On day 3,
total RNA was extracted from each of the 24 samples using TRIzol, and all samples had RNA integrity numbers
greater than 8. Libraries were prepared from 1 μg of total RNA per sample using the TruSeq stranded mRNA kit
(Illumina, Inc., San Diego, CA), according to the manufacturer’s instructions. Library quality was assessed by
electrophoretic analysis on the Agilent Bioanalyzer 2100 system. RNA-Seq libraries were sequenced in a 2 × 50
paired-end design on an Illumina HiSeq1500.
The number of reads passing filter per library ranged from 12–24 million read pairs (24–48 million total
reads. Raw reads were imported from the Illumina HiSeq1500 using bcl2fastq2 v2.17.1.14 (Illumina). Reads were
Scientific REPOrTs | (2018) 8:10954 | DOI:10.1038/s41598-018-29262-4

9

www.nature.com/scientificreports/
trimmed to remove adapter content and low quality base calls, with reads trimmed to a length of less than 25
bases removed from further analysis using Trimmomatic v0.3664. Quality of reads was assessed before and after
trimming using FastQC v0.11.5 (Babraham Institute, Cambridge, England). Reads were aligned to the human
reference genome GRCh38 using HISAT2 v2.0.465, and the resulting bam files were sorted and indexed using
SAMtools v 1.3.118. Differential gene expression was established using DESeq. 266 with a False Discovery Rate
(FDR) threshold of 0.1. Three separate comparisons were made: Th17 versus control; Th17 + FICZ versus Th17;
and Th17 + CH223191 versus Th17. In each case, expression ratios were calculated as the expression of genes in
the first-named sample group divided by the expression in the second-named sample group. A script showing the
calls to all tools, with all parameter settings, is uploaded (pipeline.sh). Expression ratios shown for each treatment
group in heat maps is normalized to the media control (Figs 2–4 and 6).

Flow cytometry. Following T cell culture, cells were resuspended in media containing phorbol 12-myristate
13-acetate (PMA, 50 ng/mL, Fisher Scientific), ionomycin (750 ng/mL, Fisher Scientific) and brefeldin A (5 ug/
mL, Tocris Bioscience) for 4 hours. Cells were then fixed, permeabilized and stained with fluorescent-labelled
antibodies for CD4, FoxP3, IL-17 and IL-22 using FoxP3 Fix/Perm Buffer Set (Biolegend). Cells were analyzed on
a Novocyte 3000 flow cytometer (Acea Biosciences, Inc.), with data analyzed using FlowJo software.
Data availability. Raw data are deposited at the National Center for Biotechnology Information’s Gene
Expression Omnibus (NCBI GEO) with accession number GSE102045.
Statistical analysis.

Data is plotted as the mean +/− standard error of the mean (SEM). Two-tailed
Student’s t-tests were used to compare experimental and control groups, with asterisks representing statistically
significant differences (*p < 0.05, **p < 0.01, ***p < 0.001). Pairwise analysis was performed where appropriate.
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